Announcements Trials
Browse Landscape

Phase

Phase 1 6

Status

Completed 6

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 6

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

nintedanib 1avelumab 1DOXO-EMCH 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Malignant Solid Tumour × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01337505 2022-02-10

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01435096 2020-03-03

BN80927 in Patients With Advanced Malignant Solid Tumors

Ipsen

Phase 1 Completed
56 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01598129 2016-10-24

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Targovax ASA

Phase 1 Completed
12 enrolled 9 charts
Other solid neoplasm

Malignant Solid Tumour

NCT01184807 2014-03-26

Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

Otsuka Beijing Research Institute

Phase 1 Completed
51 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
61 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡